BMPR1A is a transmembrane serine/threonine kinase receptor that functions as a key component of the bone morphogenetic protein (BMP) signaling pathway. Upon ligand binding (BMP2, BMP4, GDF5, GDF6), BMPR1A forms a heterotetrameric complex with type II receptors, which phosphorylate and activate BMPR1A; the activated receptor then phosphorylates SMAD transcriptional regulators to initiate downstream signaling 1. BMPR1A positively regulates chondrocyte differentiation through GDF5 interaction and mediates adipogenesis induction by GDF6 [UniProt]. The receptor also plays critical roles in cardiac regeneration, where macrophage-derived BMP2 activates BMPR1A signaling to promote cardiomyocyte proliferation 2, and in trophoblast invasion during placentation, where BMPR1A-SMAD signaling promotes invasive capacity 1. Clinically, BMPR1A mutations are significant in disease pathogenesis. Germline BMPR1A mutations cause juvenile polyposis syndrome, an autosomal dominant condition characterized by multiple gastrointestinal polyps and 39% lifetime colorectal cancer risk 34. Mutations occur in approximately 50-60% of juvenile polyposis patients 3. Additionally, BMPR1A variants associate with primary ovarian insufficiency 5. BMPR1A also participates in pathological osteogenic differentiation of renal fibroblasts contributing to kidney stone formation 6.